Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

Complement Fixation Endpoint Determined by Spectrophotometer

By LabMedica International staff writers
Posted on 18 Jun 2012
The complement fixation test is an immunological method that can be used to quantify the presence of either a specific antibody or a specific antigen in a patient's serum. More...


The qualification of a positive antibody result is based on a subjective determination of 30% lysis of sheep red blood cells, which can lead to variability in the analysis as the endpoint is observed rather than measured in a machine.

Scientists at the Associated Regional and University Pathologists Institute (ARUP; Salt Lake City, UT, USA) collected two sets of serum samples that had been sent for fungal complement fixation (CF) testing. Eleven samples sent for Coccidioides CF testing were used to assess laboratory technologist endpoint analysis precision and 60 samples sent for Coccidioides, Aspergillus, and Histoplasma mycelia CF testing were used to assess the utility of the spectrophotometric method.

Following the standard CF test, the clear supernatants were placed in round bottomed microplates alongside color standards ranging from 0% to 70% lysis in increments of 10% lysis. The plate was then analyzed by Tecan Rainbow F39200 spectrophotometer (Tecan Group Ltd.; Männedorf, Switzerland). A wavelength of 405 nm was chosen to read all samples as this is a standard wavelength available on common laboratory spectrophotometers and showed a significant optical density above background.

Of the 60 patient serum samples collected, 29 were positive and 31 were negative for CF antibodies against one of the fungal specific antigens by the non-spectrophotometric method. Of the patient serum samples with negative antibody titers, all 31 samples were verified to have negative titers by spectrophotometric analysis and did not vary from the original negative titer value. Of the 29 samples with positive CF antibody titers, 19 samples had titer endpoints that matched, and nine samples only varied endpoints by plus or minus one titer.

The authors concluded that utilizing the spectrophotometric method provided a standard reference by which 30% lysis could be accurately determined and reproduced. An inherent flaw with CF testing is the subjective nature in which the test is read that can lead to poor inter-technologist precision. If titer endpoint is inaccurately assessed, there is the potential for false positive or false negative results. The spectrophotometer method provides an objective means to obtain a titer endpoint, allowing for a reduction in errors caused by human endpoint assessment. The study was published on May 24, 2012, in the Journal of Clinical Laboratory Analysis.

Related Links:
ARUP Institute
Tecan Group Ltd.


Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.